The public health benefits and economic value of routine yellow fever vaccination in Colombia.
Öffnen
Datum
2019-05-17Autoren
Kieffer, AlexiaHoestlandt, Celine
Gil-Rojas, Yaneth
Broban, Anaïs
Castañeda Cardona, Camilo
Rosselli, Diego
Corporate Author(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
Typ
Artículo de revista
ISSN
2212-1099 / 2212-1102 (Electrónico)
Seiten
60-65
Teile diesen Datensatz
Citación
Metadata
Zur Langanzeige
PDF-Dokumente
Abstrakt
Objectives To evaluate the public health benefits and economic value of live-attenuated yellow fever (YF) 17D vaccine in Colombia. Methods A decision tree model was used to assess the theoretical impact of routine YF vaccination of 1-year-olds (no “catch-up”) during the interepidemic period from 1980 to 2002, avoiding capturing the impact of YF vaccine introduction in 2003. The vaccine was assumed to be 99% effective, to provide lifetime protection, and to cover 85% of the target population. Costs per disability-adjusted life-year (DALY) averted were computed from payer and societal perspectives. Univariate sensitivity analyses were performed. Results During the interepidemic period, routine YF vaccination would have averted 2223 nonfatal cases of YF and 65 deaths, leading to an overall reduction of 1365 DALYs. The net cost of this vaccination would have been $25 964 813 (payer’s perspective) and $16 535 465 (societal perspective). Cost per DALY averted was $19 022 and $12 114 from payer and societal perspectives, respectively (all costs in 2015 US dollars). Vaccination was considered cost-effective from both perspectives (ie, between 1- and 3-fold the gross domestic product per capita, $7158) and remains so if price per dose was $2.75 or less and $4.66 from payer and societal perspectives, respectively. Underreporting had the largest impact on the results. Conclusions Routine toddler YF vaccination in Colombia would have been considered cost-effective in the prevaccination era. This study provides insights on the value of vaccination in an upper middle-income country.
Keywords
ColombiaCost-benefit analysis
Economic evaluation
Vaccine
Yellow fever
Yellow fever vaccine
Verknüpfen Sie mit der Ressource
https://www-sciencedirect-com.ezproxy.javeriana.edu.co/science/article/pii/S221210991930038XHerkunft
Value in Health Regional Issues; Vol. 20 (2019)
Google Analytics Statistics
Collections
- Artículos [682]